UG Healthcare - RHB Invest 2018-08-24: Management Increased Capacity To Drive Efficiency

UG HEALTHCARE CORPORATION LTD SGX:41A

UG Healthcare - Management: Increased Capacity To Drive Efficiency

Maintain BUY with Target Price of SGD0.32, offering 39% upside, pegged to 12x FY19F EPS.
We met with management and came out optimistic on the outlook. In the new manufacturing block, an additional 500m (pa) glove capacity production should be in full commercialisation by Oct 2018 – this should bolster production efficiency.
We forecast FY19 & FY20 net profit growth of 16% and 23% respectively – and we believe continued glove output growth will catalyse UG Healthcare share price upside.

UG Healthcare recorded FY18 net profit growth of 77%, on the back of revenue rising 20%. The new block with production capacity of 500m units of gloves pa (raising total capacity to 2.9bn) should drive FY19 output. FY19 utilisation rate is expected to be higher y-o-y due to production efficiency.
We forecast FY19 revenue and net profit growth of 14% and 16% respectively.

~ SGinvestors.io ~ Where SG investors share

UG Healthcare is planning for another potential pa increase of 300m gloves (estimated to require capex of MYR15m) at a future date yet to be decided – this could raise total output to 3.2bn gloves.
Management will first monitor the production of the initial 500m gloves before deciding on the start date for the 300m capacity increase.

UG Healthcare intends to use the additional 500m pa glove capacity for its own branded products. Management indicated that the additional capacity will facilitate the production of the same type of gloves on a particular line, thereby minimising stoppage time to switch the type of gloves – this will enhance production efficiency. Management guided for gross profit margin of close to 20% (FY18: 16.4%) once the 500m capacity production is in steady state.
Management sees limited effects from the US-China trade war on its glove exports. This is because UG Healthcare’s gloves are for medical usage and not produced in the US.

For FY18, UG Healthcare declared a first and final dividend of SGD0.00235/share (payout ratio of 10%) – with shareholders having the option to receive either in scrip or cash. Management indicated they are aiming for a consistent dividend policy going forward.
Our Target Price of SGD0.32 is pegged to FY19F P/E of 12x, a discount to the peer average of 30x – this factors in the much smaller production output of UG Healthcare vs its other peers, most of which are listed on Bursa Malaysia.
Key risks include higher gas and raw material prices, which could narrow margins.

Leng Seng Choon CFA RHB Securities Research | https://www.rhbinvest.com.sg/ 2018-08-24

SGX Stock Analyst Report BUY Maintain BUY 0.320 Same 0.320